Chimerix (NASDAQ:CMRX) Posts Earnings Results, Beats Expectations By $0.01 EPS

Chimerix (NASDAQ:CMRX) issued its quarterly earnings data on Friday. The biopharmaceutical company reported ($0.25) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.01, Zacks reports. The business had revenue of $0.06 million during the quarter, compared to the consensus estimate of $0.31 million.

Chimerix Trading Up 0.4 %

Chimerix stock opened at $8.50 on Friday. The business’s fifty day simple moving average is $5.34 and its two-hundred day simple moving average is $2.83. Chimerix has a 12 month low of $0.75 and a 12 month high of $8.52. The company has a market capitalization of $764.46 million, a price-to-earnings ratio of -9.04 and a beta of 0.32.

Insiders Place Their Bets

In other Chimerix news, CEO Michael T. Andriole sold 7,370 shares of the business’s stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $4.52, for a total value of $33,312.40. Following the sale, the chief executive officer now directly owns 609,603 shares of the company’s stock, valued at approximately $2,755,405.56. The trade was a 1.19 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Over the last three months, insiders have sold 20,760 shares of company stock valued at $91,175. 13.10% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on CMRX shares. Wedbush reiterated a “neutral” rating and issued a $8.55 price objective (up from $7.00) on shares of Chimerix in a research report on Wednesday, March 5th. Jefferies Financial Group reiterated a “hold” rating and issued a $8.50 price objective (down from $10.00) on shares of Chimerix in a research report on Wednesday, March 5th. HC Wainwright restated a “neutral” rating and issued a $8.55 target price (down previously from $11.00) on shares of Chimerix in a research note on Wednesday, March 5th. Finally, StockNews.com assumed coverage on Chimerix in a research note on Saturday, March 15th. They issued a “hold” rating for the company.

Chimerix Company Profile

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.